TYMLOS Drug Patent Profile

When do Tymlos patents expire, and what generic alternatives are available?

Tymlos is a drug marketed by Radius and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-six patent family members in twenty-nine countries.

The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this compound. Additional details are available on the abaloparatide profile page.

DrugPatentWatch^® Generic Entry Outlook for Tymlos

Tymlos was eligible for patent challenges on April 28, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 3, 2027. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TYMLOS

International Patents:	56
US Patents:	9
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TYMLOS

Paragraph IV (Patent) Challenges for TYMLOS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TYMLOS	Subcutaneous Injection	abaloparatide	3.12 mg/1.56 mL	208743	1	2022-06-21

US Patents and Regulatory Information for TYMLOS

TYMLOS is protected by twelve US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Radius	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes
Radius	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes
Radius	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes			Y
Radius	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes			Y
Radius	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes
Radius	TYMLOS	abaloparatide	SOLUTION;SUBCUTANEOUS	208743-001	Apr 28, 2017		RX	Yes	Yes

International Patents for TYMLOS

When does loss-of-exclusivity occur for TYMLOS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

France

Hong Kong

Israel

Japan

Lithuania

Luxembourg

Mexico

Netherlands

New Zealand

Norway

Poland

Portugal

Russian Federation

Serbia

Singapore

Slovenia

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TYMLOS around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2020207653
Brazil	112021011566
Canada	3122231
China	113286818
Colombia	2021007715
European Patent Office	3908605

Supplementary Protection Certificates for TYMLOS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2073789	CR 2023 00019	Denmark		PRODUCT NAME: ABALOPARATID; REG. NO/DATE: EU/1/22/1706 20221213
2073789	CA 2023 00019	Denmark		PRODUCT NAME: ABALOPARATID; REG. NO/DATE: EU/1/22/1706 20221213
2073789	2023C/523	Belgium		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), OTHER
2073789	23/2023	Austria		PRODUCT NAME: ABALOPARATID; REGISTRATION NO/DATE: EU/1/22/1706 (MITTEILUNG) 20221213
2073789	2390018-6	Sweden		PRODUCT NAME: ABALOPARATIDE; REG. NO/DATE: EU/1/22/1706 20221213
2073789	122023000031	Germany		PRODUCT NAME: ABALOPARATID; REGISTRATION NO/DATE: EU/1/22/1706 20221212

TYMLOS (abaloparatide) investment scenario and fundamentals analysis: market size, patent/exclusivity timeline, litigation and generic risk

Last updated: July 21, 2026

Executive summary: TYMLOS (abaloparatide) is a branded PTH analog for osteoporosis that remains under active long-tail IP pressure through formulation and method-of-use filings. Revenue is concentrated in the U.S. and is exposed to payer steering, persistence risk after WAC changes, and potential biosimilar or generic substitution only after hard exclusivity and patent cliffs. For investors, the key diligence gate is the Orange Book and patent-suit timeline for abatements or Paragraph IV outcomes, followed by reimbursement durability and capacity to sustain dosing differentiation versus teriparatide and abaloparatide generic/launch-adjacent entrants.

---

What is TYMLOS (abaloparatide) and how does it compete in osteoporosis?

TYMLOS is an injectable anabolic therapy for postmenopausal women at high risk for fracture and men at high risk for fracture (where indicated on label). It is dosed by subcutaneous injection with a fixed daily regimen.

Competitive set

• Teriparatide (Forteo): PTH analog with entrenched generic risk dynamics depending on patent position in each market.
• Odanacatib is discontinued; PTH-replacement is mainly competed by anabolic alternatives and antiresorptives.
• Anti-resorptives: denosumab (Prolia/Xgeva), bisphosphonates (alendronate/ibandronate), and newer agents (e.g., romosozumab where appropriate to coverage).
• Sequencing strategy matters: anabolic-first followed by antiresorptive is common in payer guidelines.

Where TYMLOS wins clinically

• PTH analog class use is differentiated through dosing, patient selection, and guideline incorporation. In practice, competitive differentiation hinges on coverage terms, out-of-pocket, and persistence.

Commercial fundamentals that drive valuation

• Growth depends less on new-to-brand adoption and more on: payer access, persistence beyond the initial months, and site-of-care trends.
• Class switching risk exists from formulary tightening to less expensive generics of alternatives (especially if PTH analog pricing compresses).

---

What patents protect TYMLOS (abaloparatide) and how strong is the patent estate?

Answer for diligence: The strength of the TYMLOS investment case is determined by whether meaningful coverage remains around (i) the drug substance and (ii) the specific finished product and use claims. The practical investor focus is the presence of unexpired Orange Book-listed patents for the approved dosage form(s) and whether any method-of-use or formulation patents extend beyond base composition coverage.

How the TYMLOS patent estate typically breaks down

• Composition of matter (active ingredient and key chemical entities).
• Formulation patents (stability, excipients, concentration, buffer system).
• Method-of-use patents (treatment of osteoporosis and risk stratification).
• Device or delivery method claims are less likely to dominate for legacy injectables but can appear in follow-on filings.

Key investor risk mapping

• If composition-of-matter expires but formulation and method-of-use patents remain, generics may launch “at risk” only for unpatented uses or via design-around that still faces “use” carveouts.
• If method-of-use patents are asserted in Paragraph IV, settlements can delay launches even after the underlying composition expiry.

Investment implication

• A strong estate supports pricing and reduces generic competitive pressure through settlement leverage.
• A weak estate or rapid narrowing through litigation increases probability of earlier pricing compression.

(Note: A complete, accurate patent-by-patent claim map requires Orange Book and litigation docket identification tied to TYMLOS’s specific NDA listing and patent family members. This response is restricted to the investment framework only.)

---

When does TYMLOS lose exclusivity and what are the patent expiration dates that matter?

Answer for diligence: For TYMLOS, the “lose exclusivity” question should be modeled as a staircase: (1) NDA exclusivity end, then (2) earliest composition expiration, then (3) formulation and method-of-use expiration, and then (4) any stay/marker-triggered delay from Hatch-Waxman litigation.

What to model in a downside case

• A generic launch that triggers immediate net price erosion is often paired with:
  • payer formulary switches,
  • higher rebate pressure,
  • accelerated conversion of new prescriptions away from brand.

What to model in a base case

• Launch delayed by settlements or injunction outcomes.
• Competitors enter with limited-label or use carveouts, leaving brand retained for high-risk subpopulations with prescriber familiarity.

What to model in an upside case

• Extended protection via settlements, continued patent validity, and sustained reimbursement.

---

Is there any Paragraph IV litigation risk for TYMLOS, and what would it do to the stock/risk profile?

Answer for diligence: Paragraph IV risk is the primary timing driver for generic entry because it maps to: FDA approval timing, potential 180-day exclusivity for first-filer, and settlement structures.

How Paragraph IV outcomes impact investment returns

• Settlement: often yields delayed launch. Investor relevance is the date when the agreement expires and the scope of permitted formulations or labels.
• Court outcome:
  • Infringement finding typically blocks entry until patents expire.
  • Invalidity finding can accelerate launch, compressing revenue.

Investor modeling inputs

• Court timelines are long. The market typically reprices once:
  • the FDA acceptance of ANDA signals a close launch window,
  • a decision is entered,
  • a settlement agreement is disclosed.

---

What is the Orange Book status of TYMLOS and which listed patents control launch barriers?

Answer for diligence: The controlling patents are the unexpired Orange Book listings for the specific product strength, dosage form, and route tied to the NDA. For injectable brands, investors should identify which listed patents:

• are tied to formulation,
• claim method-of-use that restricts label substitution,
• include “device” or administration claim components (if any).

What investors use Orange Book for

• Estimate the earliest “safe” generic launch date for a full label.
• Determine probability of partial label carveouts that reduce brand substitution rates.
• Track litigation-to-patent mapping to anticipate settlement end.

(Orange Book listing interrogation is required for a patent-number-accurate answer. This response is limited to how the status affects the deal thesis.)

---

What generic entry risks exist for TYMLOS, and how fast would substitution happen after approval?

Answer for diligence: Substitution speed is a function of (i) label carveout feasibility, (ii) payer contracting behavior, and (iii) patient switching friction for injectable anabolic therapy.

Substitution dynamics

• If a generic is launched with full label and price discounts are meaningful, formulary switching can be fast.
• If method-of-use patents remain intact, generics may be constrained to narrower populations, limiting immediate volume displacement.

Retail and payer behavior

• Injectables face prescription and clinic administration patterns, but payers steer based on net price and coverage policies.
• Persistence matters: osteoporosis regimens are long duration, so once switched, retention can be sticky for the remainder of the treatment period.

Key investor KPI

• Brand share of new starts versus continuation scripts during the year of generic launch.

---

How does TYMLOS compare with Forteo and other anabolic osteoporosis drugs on IP and market exposure?

Answer for diligence: The competitive set for anabolic therapies determines revenue vulnerability. If competing therapies are cheaper due to earlier generic entry, payer may steer to those alternatives even if TYMLOS remains patent-protected.

Relative drivers

• Price and rebate structure across PTH analogs.
• Payer tier placement and prior authorization requirements.
• Evidence support in guideline sequences.

Investment angle

• A TYMLOS valuation multiple is more sensitive to class-level payer substitution than to brand-specific demand alone.

---

What formulations are protected for TYMLOS and which patent types most affect generic design-around?

Answer for diligence: Formulation patents are often the most practical barrier for injectable brands because generics must match stability, excipient compatibility, and shelf-life performance, or face added FDA and commercial friction.

Design-around patterns

• Altering buffer system or excipient concentrations can invite infringement risk.
• Manufacturing process changes do not automatically avoid formulation claim scope if claims are structural or functional.

Investor implication

• If formulation coverage persists late in the exclusivity timeline, the “effective” generic launch date shifts right even without composition coverage.

---

What method-of-use patents affect TYMLOS label substitution and clinical switching?

Answer for diligence: Method-of-use claims can stop generic competition even after composition expiration by limiting what the generic can claim on-label, which in turn affects payer adoption and prescriber trust.

Where method-of-use matters most

• High-risk subpopulations defined by criteria like fracture risk and treatment history.
• Sequencing patterns where prescriber behavior aligns to label indications.

Investment implication

• Even if a product can be FDA-approved for some indications, partial labeling reduces immediate volume transfer from brand.

---

What settlement agreements or licensing deals could extend TYMLOS exclusivity?

Answer for diligence: In Hatch-Waxman, settlements are common mechanisms that delay ANDA entry. Investors should treat any settlement as a date-certain variable affecting:

• launch timing,
• risk of future “modified” filings,
• scope of permitted generic variants.

What to model

• Settlement end date for each ANDA family.
• Whether there are multiple settlements across different strengths or dosage forms.
• Whether there is an agreement limiting 180-day exclusivity triggers.

(Accurate deal-term extraction requires dossier-level verification tied to TYMLOS ANDAs and NDA patent listings.)

---

How will FDA regulatory status and pathway decisions affect TYMLOS investment timing?

Answer for diligence: Post-approval regulatory milestones typically matter less for mature branded drugs unless they unlock new exclusivity extensions, new indications, or compel label updates that change generic substitution.

Key regulatory events investors track

• Label expansion or restriction that affects whether generic can market for the same use.
• Safety communications that change patient selection.
• Any postmarketing commitments that influence manufacturing equivalency.

Investment implication

• Regulatory changes can shift payer behavior and can also change generic viability if label language is tightened.

---

Manufacturing and IP barriers for generic abaloparatide: what would slow entry?

Answer for diligence: Injection products face both regulatory and execution hurdles. Even if patents are weak, manufacturing scale-up, stability validation, and cold-chain or handling requirements can slow meaningful market penetration.

Generic operational risks

• Stability and potency equivalence under real-world handling.
• Batch consistency in a peptide-like injectable environment.
• Formulation equivalence challenges if formulation patents are broad.

Investor implication

• Delayed supply reduces near-term impact on net sales even after legal permissibility.

---

Key revenue exposure: how much value is at risk from generic entry and pricing pressure?

Answer for diligence: Value-at-risk scales with:

• share of prescriptions in brand-protected use,
• payer leverage and net-to-gross spread compression risk,
• timing of generic launch relative to budget cycles.

Revenue sensitivity framework

• High sensitivity if TYMLOS has large share of formulary placements and low differentiation.
• Lower sensitivity if label carveouts persist and brand remains entrenched in high-risk protocols.

(A dollar valuation requires actual financials by company and geography. This response limits to the risk framework.)

---

What is the bottom-line investment thesis for TYMLOS under a base, bull, and bear scenario?

Base case (most probable):

• Brand holds share until the nearest patent cliff backed by Orange Book-listed claims.
• Net price gradually compresses but does not collapse before the last controlling patents expire or settlement dates pass.

Bull case:

• Patent assertions narrow slowly or courts/settlements maintain brand protection longer.
• Payer contracting remains stable due to differentiation in patient selection and persistence.

Bear case (worst case):

• A Paragraph IV ANDA results in earlier launch permission or successful design-around enabling full-label entry.
• Payer shifts accelerate, producing rapid net revenue compression in the year of launch.

---

Key Takeaways

• TYMLOS investment risk is driven primarily by Orange Book-listed controlling patents (formulation and method-of-use) and Paragraph IV litigation/settlements that shift launch timing.
• The generic substitution timeline should be modeled as a stepped exclusivity ladder, not a single “patent expiry” date.
• The decisive commercialization variable is payer steering speed after any label-permissible generic or authorized product launch.

---

FAQs

1) What patents typically extend competition for injectable osteoporosis drugs like abaloparatide?
Follow-on formulation and method-of-use claims usually extend practical exclusivity beyond composition expiration.

2) How does a label carveout limit generic impact for TYMLOS?
A carveout reduces payer formulary inclusion and prescriber willingness to switch, delaying volume displacement.

3) What signals indicate a TYMLOS generic launch is imminent?
FDA ANDA acceptance plus Paragraph IV litigation progression and settlement disclosures are the highest-signal markers.

4) Does pricing pressure usually start before legal exclusivity ends?
Often yes through rebate renegotiations and payer tender activity, but full volume displacement typically tracks legal and label permission.

5) How do competition dynamics from other anabolic therapies affect TYMLOS valuation even if TYMLOS is protected?
Class switching due to relative net pricing and payer policy can erode share without any direct generic entry.

---

References

No sources were cited in this response.